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Abstract 
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells 
with key roles in the initiation and regulation of innate and adaptive immune 
responses. As such, there is currently much interest in modulating DC function 
to improve cancer immunotherapy. Many strategies have been developed to 
target DCs in cancer, such as the administration of antigens with 
immunomodulators that mobilize and activate endogenous DCs, as well as the 
generation of DC-based vaccines. An increased understanding of DC subset 
diversity, functions and of how those are shaped by the tumour 
microenvironment could lead to improved therapies for cancer. Here, we will 
outline how different DC subsets influence immunity and tolerance in cancer 
settings and discuss the implications for both established cancer treatments and 
novel immunotherapy strategies.  
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Introduction 
Cancers originate from the uncontrolled proliferative activity of the organism’s 
cells and present characteristic hallmarks1. Despite their self-origin, tumours can 
induce immune responses. However, the incomplete elimination of tumour cells 
by the immune system can result in  the persistence of ‘immune edited’ tumours 
that are no longer detected by the immune system2. The association of infections 
with spontaneous tumour regressions and the capacity of the immune system to 
reject immunogenic tumours in preclinical models1 supports the role of the 
immune system in protection against cancers. Moreover, large-scale projects 
such as The Human Cancer Genome and the ImmunoProfiler Initiative have 
identified tumour-infiltrating immune cells — either through gene-expression 
signatures3–6 or by direct observation of these cell types7 — as important 
correlates of cancer prognosis and treatment responsiveness.  
Although dendritic cells (DCs) constitute a rare immune cell population 
within tumours and lymphoid organs, these cells are central for the initiation of 
antigen-specific immunity and tolerance8. Therefore, manipulation of DCs holds 
great potential for inducing efficient antitumour immunity. DCs promote immunity 
or tolerance by sampling and presenting antigens to T cells and through the 
secretion of immunomodulatory cytokines9,10. These DC functions are 
determined by their integration of environmental signals, which are sensed via 
surface-expressed and intracellular receptors for cytokines and pathogen- or 
danger-associated molecular patterns (PAMPs and DAMPs)11. Furthermore, 
specific DC subsets may play distinct roles in antitumour immunity, with key 
implications for therapy12,13. In this Review, we will discuss the functions of 
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different DC subsets in the tumour microenvironment (TME) and consider how 
these populations could be manipulated for therapy. 
 
1. DCs in cancer immunology 
Diversity within DCs. Distinct DC subpopulations as categorized by 
developmental, phenotypical and functional criteria have been recognized in mice 
and humans (Table 1). Mouse conventional DCs (cDCs) derive from common 
DC precursors (CDPs) in the bone marrow and comprise two main subsets, 
CD8a/CD103+ cDC1s and CD11b+ cDC2s (Table 1)10,14. B220+ plasmacytoid 
DCs (pDCs) develop from both CDPs and lymphoid progenitors, yielding 
functionally distinct pDC subsets15. Additionally, inflammatory conditions can lead 
to the CC chemokine receptor type 2 (CCR2)-dependent recruitment of 
monocytes from the blood that differentiate into monocyte-derived DCs (MoDCs) 
in peripheral tissues9,11. Notably, human DC subsets (CD141+ cDC1s, CD1c+ 
cDC2s and CD123+ pDCs) closely resemble their mouse counterparts in 
transcriptional and main functional analyses9,16 (Table 1). 
Functional specialization of DC subsets arises from their expression of different 
receptors, including pattern-recognition receptors (PRRs)9–11 (Table 1). Their T 
cell priming abilities may also differ, with pDCs showing relatively poor priming of 
naive T cells, although human and mouse pDCs can be stimulated to prime CD8+ 
T cells17–19. In contrast, mouse and human cDC1s excel at inducing cellular 
immunity against intracellular pathogens and tumours due to their efficient 
processing and cross-presentation of exogenous antigens on MHC class I 
molecules to activate CD8+ T cells and their ability to prime T helper 1 (Th1) cell 
responses10,11,14,19. Regarding the heterogeneous cDC2 subset, analysis of IRF4-
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/- mice (which lack cDC2s) suggests that these DCs are potent inducers of CD4+ 
T cell responses20,21. In addition, MoDCs are predominantly generated in 
response to inflammation and promote context-dependent differentiation of CD4+ 
T cells towards a Th1, Th2 or Th17 cell phenotype22. In the TME, DCs acquire, 
process and present tumour-associated antigens (TAAs) on MHC molecules 
(signal 1), provide costimulation (signal 2) and soluble factors (signal 3), to shape 
T cell responses (Figure 1). Below, we discuss how these DC functions within 
the TME and tumour-draining lymph nodes (TDLNs) can promote immunity or 
tolerance to tumour cells. 
 
Promotion of antitumour immunity by DCs. 
Both tumour-infiltrating DCs and DCs in TDLNs contribute to the antitumour 
immune response23,24. As CD8+ T cells are often the main effectors of antitumour 
immunity, fostering DC cross-presentation is paramount. cDC1s are associated 
with superior cross-presentation of antigens, which results in stronger CD8+ T 
cell immunity, and cDC1s additionally support Th1 polarization of CD4 T cell 
responses3,25–28. BATF3-dependent cDC1s are essential for the rejection of 
highly immunogenic tumours25. This is mediated by their cross-presentation of 
TAAs and is dependent on the regulator of vesicular trafficking WDFY429. DCs 
also require the SNARE protein SEC22B for efficient handling and cross-
presentation of antigen, leading to protection against immunogenic tumours30. By 
contrast, cDC2s and MoDCs are fundamental for presenting TAAs following 
treatment with certain cancer chemotherapies, such as anthracyclins31–33.  
Upon sensing of appropriate cues, DCs mature and express costimulatory 
molecules, such as CD80 and CD86, which control the activation or suppression 
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of T cells through interaction with CD28 or CTLA4, respectively34. Other 
costimulatory pathways involved in DC priming are a focus of research to tailor T 
cell-mediated immunity in cancer immunotherapy, including CD40-CD40L, 
CD137-CD137L, OX40-OX40L, GITR-GITRL and CD70-CD27 (Figure 1). CD40 
on DCs interacts with CD40L on T cells, leading to DC activation35. CD137L (also 
known as 4-1BBL) is expressed on antigen-presenting cells (APCs) and 
promotes the activation of CD4+ and CD8+ T cells through CD13736. OX40L on 
DCs and macrophages contributes to T cell survival, thereby favouring 
antitumour immunity37. GITRL on DCs promotes CD8+ T cell immunity and the 
resistance of T cells to regulatory T (Treg) cell-mediated immunosuppression38. 
Finally, CD70 on DCs supports CD8+ T cell cross-priming and antitumour 
immunity39.  
The effector activity of T cells depends on DC-derived cytokines, including IL-12 
and type I IFNs40 (Figure 1). In mice, IL-12 is mainly generated by cDC1s and 
contributes to Th1 and CD8+ T cell priming3,4,41. In humans, both CD141+ cDC1s 
and CD1c+ cDC2s can produce IL-12 upon TLR stimulation26,42, but IL-12 levels 
within human cancers are associated with increased cDC1 infiltration4. Type I 
IFNs are in clinical use to treat patients with cancer43 and the sensing of nucleic 
acids through the cGAS–STING pathway is fundamental for DC activation and 
type I IFN production in antitumour immunity44,45. DCs can also produce 
chemokines in the TME that attract T cells. For example, tumour-infiltrating 
cDC1s are the main producers of CXCL9 and CXCL10, which promote the 
recruitment of CD8+ T cells into the TME45. Taken together, DCs play a central 
role in antitumour immunity by conditioning the TME with soluble factors, as well 
as attracting and mediating priming of antitumour T cells. 
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DCs drive tolerance in the TME. 
Under the pressure of antitumour immunity, cancer cell variants can promote 
tolerance through DCs. Presentation of TAAs in the absence of costimulatory 
signals leads to T cell anergy8, and high engagement of inhibitory receptors can 
limit T cell effector activity (Figure 1). CTLA4 expressed on T cells binds CD80 
and CD86 on DCs with greater affinity than CD28, limiting costimulatory signalling 
and T cell activation34. PDL1 and PDL2 on DCs and other cells in the TME also 
inhibit proliferation and cytokine production by PD1-expressing activated T 
cells46. VISTA is another inducible member of the PD1 family that is expressed 
by DCs and constrains T cell antitumour immunity47. CD31, a transhomophilic 
coinhibitory molecule, induces a tolerogenic phenotype in DCs, skewing T cell 
priming towards Treg cell generation, instead of Th1 cell induction48. 
DCs can also modulate T cell function by modifying the availability of 
metabolic substrates. L-Tryptophan is essential for T cell responses and is 
depleted through its conversion to L-Kynurenine by the enzyme indoleamine 2,3-
dioxygenase 1 (IDO1) (Figure 1). IDO1 is induced in DCs upon their recognition 
of apoptotic cells or following binding of CTLA4 by CD80 and CD8649. Notably, 
increased IDO1 expression is observed in tumour-associated DCs50, and DC-
expressed IDO1 suppresses the proliferation and effector functions of CD8+ T 
cells, NK cells and plasma cells and contributes to the differentiation of Treg 
cells50. 
 
1.1. Modulation of DC function by tumours 
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In addition to TAAs and endogenous DAMPs, the TME also contains a network 
of immunosuppressive factors that can inhibit DC infiltration and subdue their 
antitumour activity (Figure 2). Targeting these immunosuppressive pathways 
therapeutically may improve the recruitment, infiltration and effector activity of T 
cells in the TME. 
 
Inhibition of cDC recruitment and differentiation.  
Few cDC1s are found in the TME owing to their suboptimal recruitment, 
differentiation or survival. However, increased  infiltration of cDC1s into the TME 
is associated with improved prognosis and responsiveness to anti-PD1 
immunotherapy in patients with cancer3,6,7. As an immune evasion mechanism, 
tumour cell-intrinsic factors can limit cDC1 recruitment. In mice, tumours with 
active β-catenin reduce CC-chemokine ligand 4 (CCL4) expression resulting in 
lower cDC1 infiltration and increased tumour growth5. Conversely, tumour-
infiltrating NK cells recruit cDC1s through production of CCL5 and XC-chemokine 
ligand 1 (XCL1)6 and foster their survival with FMS-related tyrosine kinase 3 
ligand (FLT3L)7. Yet, tumour cells can reduce NK cell viability and pro-
inflammatory chemokine secretion by producing prostaglandin E2, and this in turn 
limits cDC1 density and favours tumour growth6,51.  
 The TME also curbs DC development and differentiation. Tumour-
infiltrating lymphocytes, particularly NK cells, are the predominant producers of 
FLT3L in the TME7, and this cytokine is essential for cDC development and 
proliferation in situ 10,27. Tumour-derived factors such as VEGF can inhibit FLT3L 
activity and negatively impact cDC differentiation in vitro52. Tumour-derived 
gangliosides and prostanoids also inhibit cDC maturation and survival, as well as 
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MoDC differentiation53. As cDC precursors are found in the TME54, tumour-
derived factors could also affect local pre-DC differentiation.  
 
Impairment of DC activation and antigen presentation.  
A number of active mechanisms in the TME perturb DC functions resulting in 
insufficient T cell activation and, potentially, the induction of T cell tolerance to 
TAAs. Usually, phagocytosis of cells that have undergone immunogenic cell 
death induces activation of cDCs and effector T cell priming, but these processes 
are often inhibited in tumours. For instance, immunogenic cell death and immune 
activation in response to chemotherapy relies on the alarmin HMGB133. HMGB1 
recruits nucleic acids into DC endosomes, mediating the innate sensing of nucleic 
acids from dead tumour cells55. This activating axis is prevented in tumour-
infiltrating cDCs through high expression of TIM3, which sequesters HMGB156. 
CD47 expression in tumours inhibits detection of cancer cell-released 
mitochondrial DNA by signal regulatory protein α (SIRPα) on cDC2s that 
otherwise induces type I IFNs57. The tumour also enforces immune-regulatory 
transcriptional programmes and limits DC-mediated production of pro-
inflammatory cytokines. Versican, a tumour-derived TLR2 ligand, induces IL-10 
and IL-6 and overexpression of their receptors, which facilitates STAT3 
hyperphosphorylation in DCs and immunosuppression58. In addition, 
macrophages within tumours are a primary source of IL-10 that can abrogate IL-
12 production by cDC1s4. Chronic exposure of tumour-infiltrating mononuclear 
phagocytes to IFNγ promotes a transcriptional programme that contributes to 
immune evasion in a SOCS2-dependent manner59. Moreover, metabolites in the 
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TME can dampen DC function; for example, lactic acid is a metabolic product of 
tumour cells that impairs MoDC differentiation and activation60. 
Other TME components can also impair cross-presentation of TAAs. For 
instance, lipid peroxidation byproducts promote endoplasmic reticulum (ER) 
stress in tumour-associated cDCs, and constitutive activation of the ER stress 
sensor IRE1α leads to lipid accumulation and reduced T cell activation61. Indeed, 
lipid-laden cDCs show defective processing of exogenous antigen and impaired 
cross-presentation in cancer62. Incorporation of oxidated lipids into cDC lipid 
bodies inhibits trafficking of peptide–MHC-I complexes to the cell surface63. 
Notably, the ability of pDCs to promote antitumour immunity through 
production of type I IFN is also inhibited by immunosuppressive factors in the 
TME13. In fact, infiltration of tumours by pDCs correlates with poor patient 
prognosis in several cancers, and this seems to be due to the ability of pDCs to 
promote the expansion of Treg cell populations in an ICOSL-dependent 
manner64. Tumour-associated pDCs also fail to produce type I IFN in response 
to TLR9 ligands due to the relocation of TLR9 to late endosomal compartments65. 
However, the antitumour capacity of pDCs can be rescued by stimulation with 
TLR7 ligands17,18. 
In summary, DCs have the potential to promote efficient antitumour 
immunity by recruiting and activating different immune cells, but the TME is rich 
in immunosuppresive factors that limit the immunostimulatory capacity of DCs 
and instead skew DCs to an anti-inflammatory phenotype. In the following 
section, we consider how different cancer therapies can modulate DC functions 
to boost antitumour immunity.  
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2. DCs in the context of cancer therapy 
Cancer therapies currently used in the clinic can affect or even depend on DCs. 
Below, we discuss how DCs can influence responsiveness to these treatments 
(Figure 3). 
 
2.1. Chemotherapy and DCs. 
Certain chemotherapeutics used in the clinic — including bortezomib, 
doxorubicin, epirubicin, idarubicin and mitoxantrone, and oxaliplatin — trigger 
immunogenic cell death that promotes antitumour immunity66, and these 
responses depend on DCs32 (Figure 3A). Calreticulin is a well known opsonin (or 
‘eat me’) signal, and its exposure on the cell surface is one of the first hallmarks 
of immunogenic cell death that favours the uptake of dying tumour cells by DCs67. 
Immunogenic death of tumour cells also leads to the release of ATP that 
promotes DC recruitment (through P2RY2) and activation of the NLRP3 
inflammasome (through P2RX7)68 leading to IL-1 production. ATP also initiates 
a cell-intrinsic type I IFN response that leads to the secretion of annexin A1 and 
HMGB1 from dying tumour cells. Annexin A1 binds formyl peptide receptor 1 
(FPR1) on DCs to attract them to dying cancer cells69. HMGB1 can be sensed by 
both human and mouse DCs through TLR4, thereby promoting efficient 
processing and cross-presentation of TAAs derived from dying cancer cells33. 
Indeed, anthracyclin-induced cell death promotes MoDC recruitment into the 
TME, and these cells cross-present TAAs to CD8+ T cells31 (Figure 3A). Thus, 
chemotherapy-induced immunogenic death of cancer cells leads to the release 
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of stimulatory factors that enhance DC activation and cross-presentation of TAAs, 
thereby improving antitumour CD8+ T cell responses24.  
However, not all chemotherapies act on DCs by inducing immunogenic 
cell death and there are additional effects that can influence anti-tumour 
immunity. Chemotherapy with platinum-based drugs reduces PDL2 expression 
by DCs and cancer cells, which skews T cell responses towards Th1 cell 
differentiation and increases TAA-specific T cells70. The therapeutic efficacy of 
paclitaxel, however, is restricted by tumour-associated macrophage production 
of IL-10, which inhibits IL-12 production by DCs4. Thus, different 
chemotherapeutic agents seem to depend on specific DC subsets and their 
efficacy may be potentiated accordingly. 
 
2.2. Radiation therapy and DCs.  
Radiation therapy preferentially targets highly proliferative cells. Direct killing of 
cancer cells by radiation therapy does not, however, entirely account for its 
overall effect on tumour progression. The antitumour activity of radiation therapy 
also includes local bystander effects, such as in situ ROS production, release of 
DAMPs and cytotoxic mediators as well as modification of the immune TME. 
Moreover, radiation therapy can mediate long-range effects (out-of-field or 
abscopal effects) associated with efficient systemic cancer-specific immune 
responses mediated by immunogenic cell death induction66 that rely on cDC1 
priming of CD8+ T cells71 (Figure 3B). Cytosolic DNA released by cancer cells 
upon radiation therapy acts as a DAMP and signals through cGAS–STING to 
induce the production of type I IFN by DCs, contributing to antitumour immunity72. 
However, high non-fractionated radiation doses induce the expression of the 
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DNase TREX1, which degrades cytosolic DNA and limits its immunostimulatory 
effect on cDC1s73. Additionally, although canonical NF-kB signalling is necessary 
for the antitumour immune responses induced by radiation therapy, non-
canonical NF-kB signalling dampens antitumour immunity by inhibiting STING-
mediated induction of type I IFNs74.  
 
2.3. Small-molecule inhibitors and DCs. 
Small-molecule inhibitors target key oncogenic signalling pathways — such as 
the MAPK and PI3K–AKT–mTOR pathways — in tumour cells, but can also affect 
immune cells. Activation of STAT3 generates a type of inflammation that 
promotes tumour growth and also inhibits DC-mediated antitumour immune 
responses75. Together with MAPKs, STAT3 signalling leads to the production of 
IL-10, IL-6 and VEGF, which inhibit IL-12 production by human MoDCs. The 
STAT3 inhibitor JSI-124 can revert abnormal DC function in cancer76 and, 
accordingly, mice with a STAT3 deficiency restricted to CD11c-expressing cells 
show resistance to tumour growth77. Compounds targeting the signaling 
upstream of STAT3 have been approved for therapy of certain rare cancers and 
STAT3 inhibitors are evaluated in clinical trials78 (Table 3). Activation of the Wnt–
-catenin pathway in DCs leads to immunosuppression79, in part through an 
mTOR–IL10-dependent pathway80. Consistently, the mTOR inhibitor 
temsirolimus enhances the efficacy of DC vaccination81. The tyrosine kinase 
inhibitors sorafenib and sunitinib target similar pathways that include signalling 
downstream of VEGFR, PDGFR, FLT3 and KIT. Sorafenib mitigates the inhibitory 
effect of renal carcinoma cells on DCs82; however, as sorafenib and sunitinib also 
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target FLT3, which favours DC population expansion (Table 1), their global 
effects on DCs in the context of antitumour immunity need to be further explored.  
 
2.4. Immune checkpoint therapy and DCs. 
Antibodies that block inhibitory pathways (such as the PD1–PDL1 axis) or that 
trigger activation receptors on T cells (such as CD137) can amplify basal 
antitumour immune responses that were initially primed by DCs, with a significant 
contribution of the cDC1 subset (Figure 3C). Experimental melanomas with 
stabilized -catenin signalling associate with reduced cDC1 tumour infiltration 
and irresponsiveness to immune checkpoint blockade (ICB) therapy, which was 
rescued by transfer of preactivated cDC1s5. Moreover, tumours grafted onto 
BATF3-deficient mice, which lack cDC1s, did not respond to anti-PD1, anti-PDL1 
or anti-CD137 treatments27,28, and SEC22B-mediated cross-presentation of 
TAAs by DCs is necessary for effective PD1 blockade therapy30. In fact, 
infiltration of cDC1s within human tumours is associated with responsiveness to 
anti-PD1 treatment7.  
Synergy of TLR-mediated activation of DCs and ICB can be further 
improved by FLT3L-mediated DC expansion27,28. Further, both cGAS and STING 
are necessary for intrinsic antitumour immunity and efficient responses to anti-
PDL1, which is at least partially mediated by DCs83. Targeting of type I IFNs to 
activate cDC1s also improves anti-PDL1 treatment84, suggesting that tumour 
DCs may require activation to support ICB-induced effector T cell activity. 
In turn, ICB promotes DC accumulation within the TME. Combining 
pembrolizumab (anti-PD1) treatment with TLR9 agonists associates with an 
elevated tumour-infiltrating DC signature and, preliminarily, clinical benefit85. 
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Also, expression of checkpoint counterreceptors may be more critical on DCs 
than tumour cells as PDL1 expression by TME and TDLN DCs, but not by the 
tumour, correlates with ICB efficacy in mice and humans86.  
 
2.5. Adoptive T cell transfer and DCs. 
Transfer of activated tumour-specific T cells to cancer patients is a growing field 
with promising clinical efficacy. cDC1s attract T cells to the cancer site ensuring 
the efficacy of adoptive T cell transfer in preclinical models (Figure 3C). Indeed, 
adoptive transfer of CD8+ T cells lacks efficacy in melanomas with limited cDC1 
infiltration45. Reactivation by local DCs may also be critical, as shown in a 
pancreatic cancer model, where CCR4-transduction of CD8 T cells increases 
their capacity to interact with DCs and results in stronger antitumour activity87. 
Notably, cDC1s are necessary for effective reactivation of TAA-specific, 
circulating memory CD8+ T cells in cancer88. Moreover, activation of TNF- and 
iNOS-producing cDC2s through the CD40-CD40L axis is necessary for the 
efficacy of pre-primed TAA-specific T cell transfer89. These cDC2s function 
independently of CSF1R, although blockade of CSF1R further improves cancer 
control by reducing the number of immunosuppressive tumour-associated 
macrophages4,89. 
 
2.6. The gut microbiota and DCs? 
Increasing evidence points towards the relevance of the intestinal microbiota for 
the outcome of cancer therapies. Fecal microbiota transplantation from healthy 
patients to germ-free or antibiotics-treated mice enhanced responses to ICB, 
whereas microbiota from non-responsive cancer patients failed. Akkermansia 
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muciniphila was identified as a necessary commensal for ICB efficacy90. 
Additional microorganisms with beneficial effects on ICB efficacy in metastatic 
melanoma patients are Bifidobacterium longum, Collinsella aerofaciens, and 
Enterococcus faecium91. DCs are clear candidates to mediate this link between 
tumour immunity and the microbiota, which has a relevant impact on other 
therapies92. For instance, vancomycin-mediated modulation of the gut microbiota 
composition enhances adoptive T cell transfer efficacy in tumour-bearing mice by 
expanding cDC1s and IL-12 production93. 
 
 
3. DC-based cancer immunotherapies 
Tolerance to tumours  represents a major hurdle that must be overcome in order 
to fully harness the potential of DCs in cancer immunotherapy. Several strategies 
to revert DC-mediated tolerance are currently being pursued (Table 2 and Figure 
4). 
 
3.1  Activation and mobilization of DCs.  
Cytokines that mobilize DCs, immunostimulatory adjuvants and agents blocking 
immunosuppressive DC functions can promote the activation of DCs and T cell 
priming94 (Table 3, Figure 4A and 4B). GM-CSF directly stimulates DC 
differentiation10 (Table 1 and 3). Talimogene laherparepvec (Imlygic™, T-VEC) 
is an attenuated strain of HSV that expresses human GM-CSF; it was FDA-
approved after being shown to induce antitumour immune responses and 
improve survival in patients with advanced melanoma95. Moreover, encouraging 
results showing that FLT3L administration enhances tumour immunity, CD8+ T 
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cell activation and cancer control in mouse models (Table 1 and 3)27,96 are now 
being followed by clinical trials (NCT01811992, NCT01976585, NCT02129075 
and NCT02839265) (Figure 4B). 
Adjuvants that drive immunogenic DC activation are also being actively 
investigated, particularly derivatives of ligands for TLRs expressed by DCs66,94,97 
(Table 1 and 3, Figure 4A). BCG intravesical administration, a current standard 
treatment for superficial bladder cancer, associates with increased DC viability 
and activation98. The potency of the synthetic TLR3 agonist poly(I:C), which can 
also engage MDA5 and RIG-I receptors, has emerged as a potential cancer 
immunotherapy66. Human CD141+ cDC1s appear to be a main target of this 
therapy because of their high levels of TLR3 expression26,27 (Table 1 and 3). In 
vitro and preclinical studies show the extraordinary efficacy of poly(I:C) to activate 
DCs, induce pro-inflammatory cytokines, Th1-type immunity, NK cell activation, 
cross-presentation and anti-cancer CD8+ T cell responses culminating in 
therapeutic cancer suppression28,99,100. In clinical trials, poly(I:C) derivatives 
added to cancer (DC) vaccines improve clinical outcomes100. The TLR7/TLR8 
ligand imiquimod has been approved for local treatment of non-melanoma skin 
cancers, promoting pDC-mediated cytotoxicity101 and numerous clinical trials with 
TLR7/TLR8 agonists in cancer are ongoing (NCT-02574377, NCT02692976). 
TLR7/TLR8 agonists likely target all natural DC subsets (Table 1 and 3), activate 
NFκB and induce inflammatory cytokine secretion and costimulatory receptor 
upregulation97. Unmethylated CpG oligodeoxynucleotides (CpG-ODN) represent 
a large group of TLR9 agonists which can activate human pDCs and cDCs in vivo 
(Table 1 and 3) triggering Th1-type immunity and cancer-specific CD8+ T cell 
responses102. Interestingly, antigen and CpG co-localization in DCs correlates 
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with antitumour immunity103. The potential of CpG-ODN in combination with ICB 
is currently under evaluation in the clinic66.  
Overcoming suppression of cancer-associated DCs is another approach 
to enhance DC function (Table 3). In that regard, inhibition of IDO is being 
explored in mice and in clinical trials104. Also, STAT3 inhibitors, which can foster 
DC maturation and immunogenic functions75, are being evaluated in clinical 
trials78. 
 
3.2  Administration of antigens to boost antitumour immunity.  
In vivo administration of TAAs that can be presented (or cross-presented) by 
endogenous DCs has historically been an attractive cancer immunotherapy 
approach105. Such vaccines are mostly composed of TAAs that are delivered as 
synthetic short or long peptides (SLPs), recombinant TAA-expressing viruses, or 
whole tumour lysates (Table 3 and Figure 4C). To further ensure cancer-
specificity and fueled by recent technological advances, the use of neoantigens 
(TAAs derived from mutated proteins) is reviving hopes for TAA-based 
vaccination106. Efficacy of neoantigen vaccines may depend on the mutational 
rate of individual tumours. Patients with lung cancers or melanomas with a high 
mutational load experience a higher response rate to ICB107,108 and long-term 
survival in patients with pancreatic cancer correlates with unique qualities of 
neoantigens and increased DC and CD8+ T cell infiltrates109. Regarding the use 
of dead whole tumour lysates for vaccination, the type of induced cell death can 
influence their efficacy to induce immunity66,110. Clinically-approved whole tumour 
lysate preparations include hypochlorous acid oxidation, UVB-irradiation, freeze–
thaw cycles and hyperthermia111.  
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DC maturation is key for immunogenic antigen presentation94. Hence, 
efforts combining adjuvants with antigens for in vivo provision are on the rise 
(Table 2 and Figure 4C). TAA–adjuvants can be attached and encapsulated to 
particulate delivery systems such as single and supramolecular peptide 
conjugates (e.g. nanofibers, gels or nanoparticles), liposomes, virosomes or 
immunostimulatory complexes (ISCOMs)112. The use of self-assembling 
polymers of degradable biomaterial or nanoparticles in cancer therapy can 
intrinsically enhance pro-immunogenic DC functions113. With regard to DCs, 
medium size nanoparticles (5-100nm) most efficiently reach the lymph node and 
negatively charged adjuvants (such as poly(I:C), CpG-ODN) are easily 
internalized in cationic nanoparticles. Notably, negatively charged nanoparticles 
such as the FDA-approved poly(lactic-co-glycolic acid) (PLGA) promote DC 
maturation, cross-presentation and Th1 cell polarization113.  
Overall, much has to be learnt about optimal antigens, adjuvants and 
formulation of TAA-based cancer vaccines for which DCs are a key target to 
induce specific T cell-mediated cancer immunity. Improved knowledge on DC and 
T cell functions together with technical advances open exciting possibilities for 
future therapeutic achievements. 
 
3.3  Targeting DCs in vivo for cancer immunotherapy.  
Targeted delivery of antigens and adjuvants to DCs in vivo can improve 
antitumour immunity114 (Table 2 and Figure 4D). These therapeutic strategies 
limit potential side effects and show preclinical efficacy controlling cancer, with 
first clinical trials ongoing. C-type lectin receptors (CLRs) show a diverse 
expression pattern on DCs (Table 1) and have been used as preferential target 
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receptors. Examples include the use of DEC205, CLEC9A and Langerin to target 
cDC1s; using CLEC4A4 (also known as DCIR2) to target cDC2s; use of CLEC7A 
(also known as Dectin-1) to target cDC2s and MoDCs; use of CD209 (also known 
as DC-SIGN), the mannose receptor (MR) and macrophage galactose-type lectin 
(MGL) to target predominantly cDC2s, MoDCs and macrophages; and using 
CLEC12A to target multiple DC subsets (including cDCs, pDCs and MoDCs)114. 
Of note, antibody-conjugated antigen with adjuvant outperformed the 
administration of non-conjugated antigen115–117. Anti-DEC205 antibodies can 
target a MAGE-A3 antigen to human MoDCs, stimulating CD4+ T cell 
responses118. Full-length NY-ESO-1 fused to anti-DEC205 antibodies 
additionally promotes CD8+ T cell activation, contrary to uncoupled NY-ESO-
1119. A phase I clinical trial shows that cutaneous NY-ESO-1-coupled to anti-
DEC205 with resiquimod and/or Hiltonol induces antigen-specific antibodies and 
T cells with partial clinical responses in cancer patients without toxicity120. Primary 
human MoDCs treated with CD209/DC-SIGN-conjugated antigens (and 
adjuvants) stimulate specific T cell responses ex vivo121 as well as in humanized 
mice, limiting cancer growth. Naturally occurring blood-derived pDCs, cDC1s and 
cDC2s are efficiently targeted ex vivo by (viral) protein antigens conjugated to 
anti-CLEC12A antibody to induce cross-presentation and CD8+ T cell 
activation122. In addition, TAAs can also be conjugated to ligands for DC-specific 
receptors. Administration of MUC1 conjugated to oxidized mannan targeting the 
MR on DCs induces specific antibody and CD8+ T cell responses in breast 
cancer patients and improves cancer-free survival123. 
While the amount of TAAs and adjuvants that can be fused to these 
targeting molecules could be limited, polymer nanoparticles signify an appealing 
 21 
approach113 (Table 2 and Figure 4D). Human MoDCs efficiently internalize anti-
DEC205 antibody-coated PLGA nanoparticles loaded with MART-1 peptide and 
display enhanced cross-priming activity, compared with exposure to untargeted 
nanoparticles124. Also, anti-CLEC9A-coated PLGA nanoparticles carrying a 
GP100 SLP induce more robust CD8+ T cell priming ex vivo by human primary 
blood CD141+ cDC1s, compared with isotype-coated nanoparticles125.  
In summary, delivery of adjuvants and antigens to DCs in vivo by targeting 
DC-restricted receptors promises to enhance efficacy and reduce side effects of 
adjuvants (Table 2). 
 
4. DC vaccines for cancer  
The use of DC vaccines for cancer has been extensively investigated, with over 
200 completed clinical trials to date (Table 2 and Figure 4E). This approach 
involves the isolation or in vitro generation and amplification of autologous DCs 
followed by their ex vivo manipulation and reinfusion into cancer patients. These 
studies were predominantly undertaken in patients with melanoma, prostate 
cancer, glioblastoma or renal cell carcinoma due to the immunogenic nature of 
these cancers, and importantly, demonstrated the clinical safety and potency of 
DC vaccination to induce anti-cancer NK cell, CD8+ T cell and CD4+ T cell 
immune responses. Furthermore, considering that most enrolled patients had 
advanced cancer after failure of other treatments, the average overall response 
rate of 8-15% is noteworthy126–129. The only clinically approved DC-based vaccine 
to date is Sipuleucel-T/Provenge®, which consists of autologous blood APCs 
loaded with a recombinant fusion protein antigen composed of prostatic acid 
phosphatase and GM-CSF. It was shown to extend the median overall survival 
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rate of patients with prostate cancer patients by about 4 months130. Recent 
scientific advances suggest the efficacy of DC vaccines could be further improved 
by considering various other factors, which we discuss below.  
Influence of DC type. Autologous MoDCs obtained from patient CD14+ 
blood monocytes or by differentiation of CD34+ progenitors are effective against 
different cancer types. Phase III clinical trials using MoDC-based cancer 
vaccination are ongoing in uveal melanoma (NCT01983748, autologous tumour 
RNA antigen), castration resistant prostate cancer (NCT02111577, irradiated 
prostate cancer cell line antigen) as well as metastatic colorectal cancer 
(NCT02503150, autologous tumour lysate) and preliminary results of a large trial 
(NCT00045968) adding autologous tumour lysate-loaded MoDC vaccination 
(DCVax®‑L) to standard treatment of glioblastoma reports clinical safety and a 
potential increase in survival131.  
Naturally occurring DC subsets harbour greater antigen-presentation 
capabilities than in vitro-generated MoDCs due to higher MHC molecule 
expression and functional specialization and are proposed as the basis of next-
generation vaccines10,127,129 (Table 1). Preclinical mouse studies show the 
efficacy of primary pDCs to induce CD8+ T cell activation in certain settings17. 
However, in a comparative experimental glioma vaccination study, tumour-
bearing mice-derived cDCs, rather than pDCs, were more effective in prolonging 
survival132. Another comparative study in mice reported the efficacy of 
prophylactic transfer of tumour-derived cDC1s and cDC2s to reduce growth of a 
subsequently grafted tumour. Interestingly, cDC1s induce CD8+ and CD4+ 
immunity, while preventive vaccination with cDC2s relies on Th17 cell 
responses133. 
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Advances in natural DC isolation techniques from leukapheresis products 
have led to the first clinical trials in cancer patients. One clinical trial uses enriched 
blood cDCs and pDCs from patients with melanoma after FLT3L treatment. This 
personalized DC preparation, stimulated with CD40L and pulsed with cancer-
germline antigen peptides, generates antigen-specific T cell responses134. 
Human blood DC subsets have also been assessed for their suitability for cancer 
vaccination separately. CD303+ pDCs obtained from melanoma patient 
leukapheresis products induce specific immunity in some patients when loaded 
with TAA peptides18. Two clinical trials report the safety and feasibility of patient 
blood-derived CD1c+ cDC2s loaded ex vivo with TAA peptides in prostate cancer 
and melanoma135,136, the latter additionally showing vaccine-specific CD8+ T cell 
responses that correlated with improved progression-free survival in 4 out of 14 
patients. These studies led to clinical trials using pDCs and/or cDC2s in various 
cancer settings (NCT02993315, NCT02692976, NCT02574377, NCT03747744 
and NCT03707808). Notably, to our knowledge, the potential of naturally 
occurring mouse or human cDC1s for therapeutic cancer vaccination was not 
assessed so far, despite their correlation with favourable prognosis3,5,6,23 and the 
data supporting their importance for CD8+ T cell cross-priming and induction of 
antitumour immune responses (see previous sections).  
As potential limitations, natural DCs from cancer patients may be dysfunctional 
(see previous sections)129,137 and only represent a small blood cell population 
(<1%)26. New cell culture techniques generating cells largely equivalent to natural 
DC subsets may overcome issues of DC availability138,139. Notably, cytokine 
secretion by pDC (IFN), cDC1 and cDC2 (TNF and IL-12) subsets from breast 
cancer patients and healthy donors was equal upon R848 stimulation137, 
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highlighting the need for proper DC activation to overcome DC dysfunction before 
re-infusion. 
 Antigen-loading of DCs. The ideal antigen for ex vivo DC-loading depends 
on the precise clinical setting (for example, TAA expression and the availability 
of tumour tissue, Table 3); however, the nature of the antigen and its 
internalization influences the induction and upholding of immune reposes by DCs 
(Table 2). Compared with untargeted delivery, coupling of TAA to DC-specific 
antibodies promotes cross-presentation by human MoDCs and cDC1s, leading 
to TAA-specific CD8+ T cell responses124,125,140. Adoptive transfer of patient-
specific neoantigen-loaded MoDCs to melanoma patients amplifies the diversity 
of neoantigen-specific T cells141, a strategy currently being tested in several 
clinical trial phases (e.g. NCT03300843, NCT03674073, NCT01885702). Human 
MoDCs electro-fused with breast cancer cells (as antigen source) promote 
stronger CD8+ T cell responses than MoDCs cultured with live cancer cells142. In 
a phase I clinical trial, three antigen-delivery regimes for MoDCs were compared 
with cocultured DCs and irradiated (dead) melanoma cells achieving slightly 
higher immune responses than freeze-thaw melanoma cell lysate or DC-
melanoma cell fusion143. 
DC maturation and activation. In the steady state, an important function of 
DCs is to maintain central and peripheral tolerance, which likely contributed to 
the disappointment of first vaccination attempts with steady-state immature 
DCs127. Indeed, early clinical studies proved the importance of MoDC maturation 
for their migration and induction of effector T cells leading to the creation of MoDC 
maturation cocktails with diverse activating cues, such as cytokines, PAMPs and 
DAMPs (Table 3). Of note, the nature of these adjuvants and activating agents 
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has to be tailored towards each DC subset since their efficacy depends on the 
pathogen-recognition receptor profile (Table 1).  
 Route and dosage of DC vaccination. Migration of transferred DCs to 
TDLNs for T cell priming is important for DC vaccination efficacy. This feature is 
not only influenced by DC maturation and activation, but also depends on the 
injection site. Subcutaneous, intratumoural, intravenous, intradermal, intranodal 
and, recently, intralymphatic represent tested DC vaccine administration 
routes144,145. While the clinically-approved Sipuleucel-T/Provenge® vaccine is 
safely delivered intravenously130, the most effective fashion of DC delivery is 
debated and may depend on the cancer type. Intriguingly, the administration 
route and tissue location of DCs seem to imprint migration cues in responding T 
lymphocytes to recirculate to cancer tissue146. Pre-conditioning of the DC 
vaccination site and injection of higher numbers of DCs was suggested to 
improve vaccine efficacy127,145 , although some studies report opposite results147. 
However, these differences might rely on the preconditioning stimulus and DC 
subset. For DC vaccination, the minimal required DC number remains to be 
defined, while the largely limiting factor is commonly sufficient 
generation/isolation of DCs148.  
Combination treatments. A daunting challenge of DC vaccination and 
immunotherapy in general is the immunosuppressive microenvironment created 
by the tumour. Such immunosuppression is influenced by tumour type and 
burden, immunological fitness of the patient as well as the immunologic, 
metabolic and hypoxic features of the TME and is manifested by antigen loss or 
masking and production of immunosuppressive mediators/cytokines, among 
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other factors126–129. Overcoming this immunosuppression is crucial for improving 
DC vaccination. 
Notably, the action of DCs is associated or even underlies efficacy of 
currently used cancer therapies such as ICB, chemotherapy and radiotherapy 
(discussed in previous sections). Thus, the combination of DC vaccination with 
those therapies has been proposed126,149. Especially, DC vaccination in 
combination with ICB appears ideal as transferred DCs might foster initial 
antigen-specific effector T cell activation127.  
In summary, antigen-loading and maturation of DCs in a controlled 
environment ex vivo offers several advantages such as avoiding tolerogenic 
signals, a wide selection of adjuvants and antigens (Table 3) as well as quality 
control before inoculation. Some drawbacks include the complexity of optimizing 
the precise conditions and higher costs due to the need of personalized cell-
therapy products (Table 2 and Figure 4E). The power and potential of DC 
vaccination for cancer immunotherapy lies in its clinical safety and its potential 
synergy with established treatments.  
 
5. Perspective 
Recent success has fueled the interest in improving antitumour T cell immunity 
in cancer therapy. DCs are the most potent APCs able to activate naive T cells 
and can induce immune memory responses in cancer. While DCs are often found 
to be dysfunctional or tolerogenic in the TME, improved knowledge on how DCs 
are regulated in this context may allow for therapeutic exploitation in several 
clinical settings. A topic of interest is how different DC subsets may lead to unique 
functional immune responses in the context of cancer. In that regard, the cDC1 
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subset is linked to induction of cancer-controlling immunity and improved survival 
in certain cancer types3,5–7,12,25,27–29,45. However, MoDCs are fundamental during 
treatment with immunogenic cell death-inducing chemotherapy agents and 
radiotherapy31–33 and cDC2s can also be key in particular cancer types133. DCs 
can promote the efficacy of established cancer therapies, but the development of 
optimal vaccination strategies still requires a better understanding of DC biology 
and functions. Achievements in preclinical studies fosters the use of DCs to find 
more efficient therapeutic treatments in clinical trials. Approaches to attain so 
include administration in conjunction with (neo-)antigens, mobilization of 
endogenous DCs and the use of stimulating adjuvants. More refined and precise 
DC-targeting might enhance efficacy of those strategies. DC vaccination 
approaches may be particularly effective to delay or prevent both relapse and 
metastasis after debulking surgeries. Overall, we need to learn more concerning 
how we can optimally manipulate and exploit specific DC subsets with specialized 
functions to orchestrate efficacious immune responses against cancer.  
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DC subset 
 
Morphology 
 
Presence      
in vivo 
Development, 
growth & 
transcription 
factors 
Main surface markers 
Main pathogen 
recognition receptors 
Main functional specialization 
Mouse Human Mouse Human Mouse Human 
 
 
 
 
 
Plasmacytoid 
DCs (pDCs) 
 
 
 
 
 
Plasma-cell 
like 
 
Resident in 
lymphoid 
tissues; found 
in blood, lung 
(mouse) and 
tonsil 
(human) 
 
 
 
 
HSC, CDP / 
depend on 
FLT3L / 
E2-2, IRF7 
CD11c-low, 
MHC-II-low, 
B220+, 
CD317+, 
SiglecH+, 
CD172a+, 
CD209+, 
CCR2-low, 
CCR9+, 
CXCR3+ 
 
CD11c-, 
HLA-DR- 
low, 
CD123+, 
CD303 
(CLEC4C)+, 
CD304+, 
CCR2+, 
CXCR3+ 
 
 
TLR7, 
TLR9, 
TLR12, 
RLR, 
STING, 
Clec12A 
 
 
 
TLR7, 
TLR9, 
RLR, 
STING, 
CLEC12A 
 
 
Control of viral infections, Type I 
interferon secretion. Generally 
poor antigen-presentation, but 
can be stimulated to activate 
CD8+ T cells (cross- 
presentation). Implicated  in 
cancer cell killing. 
Type I and III interferon  
secretion upon acute or chronic 
viral infection. Can be stimulated 
to activate CD8+ T cells (cross- 
presentation). Implicated in 
progression of autoimmune 
diseases. Role in tolerogenic 
settings poorly described, but 
correlate with poor prognosis in 
cancer. 
 
 
 
 
Conventional 
type 1 DCs 
(cDC1s) 
 
 
 
 
 
 
 
 
Irregular, 
stellate 
shape with 
extensive 
cell 
membrane 
processes 
 
 
 
 
 
 
Resident in 
lymphoid 
tissues and 
found in 
blood. 
Migratory 
subsets are 
present in 
peripheral 
tissues and 
LNs. 
 
HSC, CDP, 
pre- 
cDC / depend 
on FLT3L, 
GM- CSF / 
BATF3, IRF8, 
BCL6, ID2, 
ZBTB46, 
NFIL3, 
NOTCH 
signaling 
CD11c+, 
MHCII+, 
CD8α+, 
(resident) 
CD103+, 
(migratory) 
CD24+, 
XCR1+, 
Clec9A+, 
DEC205+ 
 
 
CD11c+/low 
, HLA-DR+, 
CD141+, 
XCR1+, 
CLEC9A+, 
DEC205+ 
 
 
 
 
TLR2-4, 
TLR11-13, 
STING, 
Clec12A 
 
 
TLR1, 
TLR3, 
TLR6, 
TLR8, 
TLR10, 
STING, 
CLEC12A 
 
Cellular immunity against 
tumours and intracellular 
pathogens, CD8+ T cell and Th1 
type immunity. Specialized on 
cross-presentation. High 
secretion of IL-12, type I and III 
interferons. 
Implicated in self-tolerance in 
the steady-state (via cross- 
presentation). 
Cellular immunity against 
tumours and intracellular 
pathogens, CD8+ T cell and 
Th1 type immunity. Specialized 
on cross-presentation. Produce 
type  I and III interferon and 
IL-12 at lower levels. Correlate 
with beneficial prognosis in 
cancer. 
Role in tolerogenic settings 
poorly described. 
 
 
 
 
Conventional 
type 2 DCs 
(cDC2s) 
 
 
HSC, CDP, 
pre- 
cDC /  depend 
on FLT3L, GM- 
CSF / IRF4, 
ID2, RBPJ, 
NOTCH2, 
KLF4, ZBTB46 
 
 
 
 
CD11c+, 
MHCII+, 
CD11b+/hi, 
CD172a+ 
 
 
 
CD11c+, 
HLA-DR+, 
CD1c+, 
CD11b+, 
CD172a+ 
 
TLR1-2, 
TLR4-9, 
TLR13, 
RLR, NLR, 
STING, 
Clec4A, 
Clec6A, 
Clec7A, 
(Clec12A) 
 
TLR1-9, 
RLR, NLR, 
STING, 
CLEC4A, 
CLEC6A, 
CLEC7A, 
CLEC10A, 
CLEC12A 
 
Context-dependent, large 
repertoire of PRRs and pro- and 
anti-inflammatory cytokines. 
Humoral and cellular immunity 
against extracellular pathogens, 
T follicular helper cell, Th2 and 
Th17 type immunity. Implicated 
in Th17 homeostasis in gut and 
lung. 
Context-dependent, large 
repertoire of PRRs and pro- and 
anti-inflammatory cytokines, 
including IL-12. Mainly induce 
Th17, but also Th1, Th2,  Treg 
and CD8+ T cell (cross- 
presentation) activation, 
depending on the context and 
precise cDC2 subpolulation. 
Maintain Treg/Th17 
homeostasis in gut (and lung). 
 
 
 
 
Monocyte- 
derived DCs 
(moDCs) 
 
 
 
 
 
Context- 
dependent 
Differentiate 
from 
monocytes in 
peripheral 
tissues upon 
inflammation. 
Resident in 
skin, lung and 
intestine. 
 
 
Monocytes / 
mainly depend 
on CSF-1R, in 
vitro GM-CSF 
+ IL-4 / MAFB, 
KLF4, 
express 
ZBTB46 
 
CD11c+, 
MHCII+, 
CD11b+, 
Ly6C+, 
CD64+, 
CD206+, 
CD209+, 
CD14+, 
CCR2+ 
CD11c+, 
HLA-DR+, 
CD1c+, 
CD11b+, 
CD14+, 
CD64+, 
CD206+, 
CD209+, 
CD172a+, 
CCR2+ 
 
 
 
 
 
Not well 
defined 
 
 
 
 
 
Not well 
defined 
Mainly generated during 
inflammation conditioning their 
functions: Direct anti-microbial 
effector functions and induction 
of CD8+ T cell, Th1, Th2 and 
Th17-type immunity. Implicated 
in Treg generation and immune- 
suppression in cancer as well as 
in autoimmune pathogenesis. 
Involved in regulatory functions 
in steady state skin. 
 
 
Mostly studied in vitro, functions 
depend on signals/stimulation 
and can be skewed towards 
CD8+ T cell, Treg, Th1, Th2 and 
Th17-type immunity. Implicated 
in regulatory functions in steady 
state skin. 
 
 
Table 1: Human and mouse DC subsets 
 
Overview on characteristics of the predominant DC subsets found in humans and mice: 
plasmacytoid DCs (pDCs), conventional/classical type I (cDC1s) and type 2 (cDC2s) DCs as well 
as monocyte-derived DCs (MoDCs). 
 
BATF3, Basic Leucine Zipper ATF-Like Transcription Factor 3; BCL6, B-cell lymphoma 6 protein; 
CDP, common DC progenitor; CSF-1R, Colony-stimulating factor 1 receptor; FLT3L, FMS-like 
tyrosine kinase 3 ligand; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HSC, 
hematopoietic stem cell; ID2, inhibitor of DNA binding 2; IRF, Interferon-regulatory factor; KLF4, 
Kruppel-like factor 4; MAFB, MAF BZIP Transcription Factor B; MHC, major histocompatibility 
complex; NFIL3, Nuclear Factor, Interleukin 3 Regulated; NLR, NOD-like receptor; PRR, 
pathogen recognition receptor; RBPJ, Recombining binding protein suppressor of hairless; RLR, 
RIG-I-like receptor; Th, CD4+ T helper cell; TLR, Toll-like receptor; Treg, regulatory CD4+ T cell; 
ZBTB46, Zinc Finger And BTB Domain Containing 46.  
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Therapeutic 
strategy 
 
Costs 
 
Applicability 
Potential side 
effects 
 
Feasibility 
 
Other advantages 
Other 
disadvantages 
 
Examples 
 
Reported successes 
 
Free / soluble 
adjuvant/DC 
activation 
factor(s) 
 
 
 
Low 
 
 
 
Universal 
 
 
High, (local or 
systemic 
inflammation) 
 
 
 
Easy 
 
 
 
/ 
 
Low persistence, 
targeted cells 
unclear, antigen-- 
unspecific 
BCG, picibanil, 
monophosphoryl lipid 
A (TLR2/4), poly(I:C) 
(TLR3), imiquimod, 
resiquimod, VTX--2337 
(TLR7/8), CpG--ODN 
(TLR9) 
Imiquimod licensed for skin 
cancer and BCG for bladder 
cancer (BCG mechanisms 
poorly understood). 
Adjuvants are part of most 
DC-based immunotherapies 
under evaluation. 
 
 
 
DC mobilizing 
agent(s) 
 
 
 
Low 
 
 
 
Universal 
 
Moderate 
(systemic 
effects 
possible) 
 
 
 
Easy 
 
 
 
/ 
 
Eventual 
immaturity and 
dysfunction of 
expanded DCs, 
antigen--unspecific 
 
 
 
GM-CSF, FLT3L 
Clinically approved 
Talimogene laherparepvec 
(oncolytic virus + GM-CSF). 
GM-CSF is added to 
numerous DC-based 
immunotherapies.  FLT3L is 
evaluated in trials. 
 
 
Free / solube 
antigen (TAAs, 
TCL, NAs) 
 
 
 
Low* 
 
 
 
 
 
 
 
 
 
 
 
 
Universal 
(TCL), 
Limited (TAA 
expression) or 
Personalized 
(NAs) 
 
 
Moderate / 
Low, adjuvant- 
dependent  
 
 
 
Easy* 
 
 
 
Large antigen diversity 
possible 
Rapid clearance 
by phagocytic 
cells, targeted 
cells unclear, can 
cause tolerance 
w/o adjuvant 
 
Synthetic peptides, 
SLPs, mRNA/DNA, 
expressing viruses, 
dead whole tumour 
material 
Neoantigens show great 
promise. Otherwise generally 
poor outcomes, clinical trials 
ongoing. Antigens are part of 
most DC-based 
immunotherapies under 
evaluation. 
Adjuvant/antigen 
carriers 
(untargeted 
emulsions, 
nanoparticles 
etc.) 
 
 
 
Moderate / 
Low* 
 
Moderate 
(local or 
systemic 
inflammation) 
 
 
 
Easy / 
Moderate* 
 
Protection from 
antigen clearance, 
slow release, 
additional adjuvancy 
 
Targeted cells 
unclear, relies on 
local DCs, 
potential effects 
of carriers on DCs 
Peptide/protein 
conjugates (e.g. 
nanoparticles), 
liposomes, virosomes, 
ISCOMs, water/oil 
emulsions 
 
Emulsion Montanide ISA™ 
51 (carrying EGF+P64k) 
licensed for lung cancer. 
Many clinical trials ongoing. 
 
DC-targeted 
adjuvant/antigen 
delivery (DC- 
specific antibody- 
coupled) 
 
 
 
Moderate / 
Low* 
 
 
Low, antibody 
specificity- 
dependent 
 
 
 
Easy / 
Moderate* 
 
Specific DC-targeted, 
antibody uptake can 
enhance cross- 
presentation 
Rapid clearance, 
limited to 
identified 
TAAs/NAs, TCL 
challenging, 
unspecificity of 
antibody 
DC-specific antibodies 
or receptor-ligands: 
anti-DEC205, anti- 
Clec4A, anti-CD209, 
anti-Clec7A, 
anti-Clec12A, anti-MR, 
oxidized mannan 
Early clinical trials ongoing: 
e.g. anti-DEC205--coupled NY- 
ESO-1-(+ adjuvants) ; MR 
targeting with anti-MR-
-conjugated hCG-b or 
oxidized mannan-coupled 
MUC1. 
DC-targeted 
adjuvant/antigen  
carrier delivery 
(e.g. antibody- 
coupled 
nanoparticles) 
 
 
 
Moderate / 
Low* 
 
 
Low, antibody 
specificity- 
dependent 
 
 
 
Moderate / 
Easy* 
Specific DC-targeted, 
protected co-delivery 
of adjuvant/antigen, 
antibody uptake can 
enhance cross-
presentation, antigen 
diversity possible 
 
Potential effects 
of carriers on DCs, 
unspecificity of 
antibody 
 
PLGA or ferrous 
nanoparticles 
conjugated with anti-
Clec9A, anti-DEC205, 
anti-Clec4A 
 
 
 
Promising pre-clinical results 
in mice and humans. 
 
 
 
 
Adoptive transfer 
of         
adjuvant/antigen-- 
loaded DCs 
 
 
 
 
 
High*, can 
be   
automated 
 
 
 
 
 
Personalized 
DC 
preparation 
 
 
 
 
 
 
Low 
 
 
 
 
 
Difficult, can 
be    
automated 
Specific DC subsets, 
controlled 
adjuvant/antigen co- 
delivery, unlimited 
adjuvant/antigen 
diversity, quality 
control, antibody- 
mediated delivery 
possible, personalized 
product might 
enhance efficacy 
 
 
 
 
Limited cell 
number, 
leukapheresis 
necessary 
 
 
 
 
In vitro generated 
moDCs, blood APCs 
and natural DC subsets 
activated and antigen-
loaded ex vivo 
Licensed Sipuleucel-
T/Provenge® for prostate 
cancer. About 200 Clinical 
trials generally showed 
induction of anti-cancer 
immunity and mild overall 
responses. Evaluation of 
neoantigen-loaded DCs, 
therapy combinations and 
stage III clinical trials with 
moDCs and natural DCs 
ongoing. 
 
Table 2. Approaches targeting DCs for cancer immunotherapy: advantages and drawbacks  
 
Characteristics of different dendritic cell (DC)-based therapeutic strategies are summarized. 
References are provided throughout the main text. 
 
APC, antigen-presenting cell; BCG, Bacille Calmette-Guérin; CpG-ODN, Unmethylated CpG 
oligodeoxynucleotides; EGF, Epidermal growth factor; FLT3L, FMS-like tyrosine kinase 3 ligand; 
GM-CSF, Granulocyte-macrophage colony-stimulating factor; hCG-b, Human gonadotropin-b 
chain; ISCOM, immunostimulatory complexes; moDC, monocyte-derived DC; MR, mannose 
receptor; MUC1, Mucin 1 cell surface associated; NA, neoantigen; NY-ESO-1, New York 
esophageal squamous cell carcinoma 1; P64k, meningococcal protein antigen of 64 kDa; PLGA, 
poly(latic-co-glycolic acid); SLP, synthetic long antigen peptides; TAA, tumour-associated 
antigen; TCL, whole tumour cell lysate; TLR, Toll-like receptor; XP, cross-presentation.  
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Agents promoting immunogenic functions of dendritic cells in cancer 
Compounds Characteristics Effect on DCs and immune consequences Cancer-treatment approved examples 
 
GM-CSF 
Cytokine essential for cDC 
development 
 
cDC mobilization, attraction and maturation 
 
Imlygic™ approved, others in clinical trials 
 
FLT3L 
Cytokine essential for cDC 
development 
 
cDC1 & cDC2 mobilization/expansion 
 
CDX-301 in clinical trials 
TLR2/4 
agonists 
Various synthetic or microbial-
derived PRR ligands 
Mainly human cDC2 activation: cytokines, CD8+ T cell 
induction, survival extension 
BCG, picibanil and monophosphoryl lipid A approved, 
others in clinical trials 
 
TLR3 agonists 
Synthetic PRR ligands, mainly 
poly(I:C) derivatives 
Direct cancer cell cytotoxicity & cDC (mainly human 
cDC1) activation: cytokines, Th1 immunity, NK and 
CD8+ T cell induction 
Hiltonol™ (poly I:C LC), Ampligen™ (poly I:C 12U) & BO- 
112 in clinical trials 
TLR7/8 
agonists 
Various ligands for PRRs 
TLR7 and/or TLR8, mainly 
imidazoquinolines 
Human pDC & cDC activation: cytokines, Th1 immunity, 
CD8+ T cell induction, tumouricidal DC activity 
Imiquimod approved, others in clinical trials (resiquimod, 
VTX-2337, protamine RNA) 
 
TLR9 agonists 
Synthetic PRR ligands, 
unmethylated CpG 
oligodeoxynucleotides 
Human pDC & cDC activation: cytokines, Th1 immunity, 
CD8+ T cell induction 
Numerous compounds in clinical trials (including CPG- 
7909 and CpG--685) 
 
IDO inhibitors 
Targeting of indoleamine 2,3- 
dioxygenase enzyme 
Prevention of DC-derived IDO-mediated tryptophan-
-depletion, tolerogenic functions and T cell anergy 
induction 
Numerous compounds in clinical trials (including INCB 
024360 and Indoximod) 
STAT3 
inhibitors 
Small molecules/ monoclonal 
antibodies blocking STAT3 signaling 
DC activation, prevention of immune-suppressive DC 
functions 
IL‑6/JAK/STAT3 signalling  blockers approved 
(Siltuximab, Tocilizumab, Ruxolitinib), STAT3 inhibitors in 
clinical trials 
 
Types of tumour associated antigens for DC-mediated anti-cancer T cell activation 
TAA type 
Examples for proteins/ 
source for TAAs 
Cancer 
specificity 
Advantages Disadvantages 
Differentiation 
antigens 
Melan-A/MART1, 
GP100, tyrosinase, 
PAP, CEA 
 
Low 
High prevalence, cheap off-the-shelf products, allow 
conjugation 
 
High probability of unspecificity and side effects 
Overexpressed 
antigens 
 
WT1, MUC1, ERBB2 
 
Low 
High prevalence, often cancer-causative 
(oncogenes), cheap off-the-shelf products, allow 
conjugation 
 
High probability of unspecificity and side effects 
 
Viral antigens 
HPV-, EBV-derived 
proteins 
 
High 
Very specific, often cancer-causative (oncoviruses), 
allow conjugation 
 
Limited prevalence of virus-associated tumours 
Cancer-- 
germline / 
cancer-testis 
antigens 
NY-ESO-1, MAGE (e.g. 
MAGE-A3), GAGE and 
BAGE  protein families 
 
High 
 
Specific, represent 50% of T cell-recognized 
TAAs, cheap off-the-shelf products, allow 
conjugation 
 
Not exclusive to cancer (side effects possible, e.g. 
MAGE- A3), limited prevalence 
Mutated 
neoantigens 
Mutated proteins 
specific to (individual) 
cancers 
 
Highest 
Very specific, high efficacy being often unique to 
cancer / patient, might allow conjugation 
Expensive, labor- & technology-intensive personalized 
product 
 
Whole tumour 
antigens 
Lysate of autologous or 
allogeineic dead cancer 
material (e.g. GVAX, 
Melacine®, OncoVAX) 
 
Variable 
Complete cancer--patient--tailored TAA selection, no 
need for neoantigens identification. Contain additional 
DC-activating factors improving immunity, cheap 
Limiting cancer material (autologous), suboptimal 
matching (allogeneic), uncontrolled TAA quality, some 
probability of side effects, more difficult to conjugate 
 
Table 3. Adjuvants and antigens frequently used for in vivo/in vitro DC activation in cancer  
 
Overview of factors to enhance anti-tumourigenic and pro-inflammatory functions of dendritic cells 
(DCs) and tumour-associated antigens (TAAs) for DC-loading exploited in the clinic. References 
are provided throughout the main text. 
 
BAGE, B melanoma antigen; CEA, carcinoembryonic antigen; EBV, Epstein-Barr virus; ERBB2, 
receptor tyrosine-protein kinase erbB-2; FLT3L, FMS-like tyrosine kinase 3 ligand; GAGE, G 
antigen; GM-CSF, Granulocyte-macrophage colony-stimulating factor; GP100, glycoprotein 100; 
HPV, human papillomavirus; IDO, indoleamine 2,3-dioxygenase; MAGE, melanoma-associated 
antigen; MART1, melanoma antigen recognized by T cells 1; MUC1, Mucin 1 cell surface 
associated; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PAP, prostatic acid 
phosphatase; PRR, pattern recognition receptor; STAT3, signal transducer and activator of 
transcription 3; Th1, CD4+ T helper cell type 1; TLR, Toll-like receptor; WT1, Wilms' tumour 1.  
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Figure 1. Mechanisms through which DCs induce immunity or tolerance in T cells. 
 
To control T cell activity, DCs can present TAAs on MHC-I and MHC-II molecules. However, that 
is not sufficient to prime effective antitumour immunity, which requires a positive signaling (blue 
arrows and receptors) through costimulatory molecules (belonging to the B7 and TNF protein 
families) and soluble factors, such as IL-12 and type I IFN. Conversely, inhibitory mechanisms 
(red arrows and receptors) limit T cell activation.  
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Figure 2. Regulation of DC function by tumours. 
 
Cancer suppresses DC-mediated antitumour immunity by impairing the indicated main aspects 
of DC biology. 1. Decreased availability of FLT3L in the TME can reduce the terminal 
differentiation of pre-DCs, as well as tumour-derived prostanoids and gangliosides can affect both 
in situ or BM generation of DCs. 2. Tumours can block the infiltration of dendritic cells by reducing 
the expression of DC-attracting chemokines like CCL4, or by preventing other attractors such as 
NK cells from doing so. 3. Tumours avoid detection by DCs by limiting the release of activating 
molecular cues, such as TREX1 that degrades ATP and prevents MoDC recruitment into the TME 
or TIM3 that avoids HMGB1-mediated detection of dying cancer cells. 4. Tumours modify DC 
metabolism to impair their functionality, by increasing the accumulation of truncated fatty acids 
and by decreasing the availability of nutrients and oxygen. 5. TAA handling and (cross-) 
presentation are impaired by tumours by promoting the accumulation of half-degraded lipids that 
interfere with cargo trafficking within DCs. 6. Tumours can regulate the appropriate maturation of 
DCs by direct or indirect (via CSF1-recruited tumour-associated macrophages) production of 
soluble compounds such as IL-10, TGF, IL-6 or VEGF, which end up hijacking standard signaling 
pathways, as it occurs with the hyperphosphorylation of STAT3. 7. Tumours can compromise DC 
viability by targeting factors such as the hypoxia response, ER stress, or the Bcl-2 protein family. 
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Figure 3. Dendritic cells in the context of cancer therapy 
 
DCs play an essential role in the generation of efficient antitumour immune responses triggered 
by different therapeutic strategies against cancer. (A) MoDCs mediate antitumour immunity 
triggered by chemotherapy and local radiation therapy-induced immunogenic cell death. In 
summary, MoDCs are strongly recruited into the TME of tumours treated with immunogenic cell 
death-inducers, and prime robust CD8 T cell responses. (B) cDC1s contribute to the out-of-field 
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(abscopal) effects of in situ radiation therapy, another inducer of immunogenic cell death. This 
response relies on the recognition of cancer cell-derived cytosolic DNA by the cGAS-STING 
pathway. (C) cDC1s strongly associate with the efficacy of immune checkpoint therapy and 
adoptive cell transfer, due to their capacity to prime T cell responses locally and in the TDLNs, to 
recruit T cells into the TME, and to condition the TME by producing soluble factors.  
 
 
Figure 4. Exploiting dendritic cells for cancer immunotherapy 
 
Principles underlying functionality of therapeutic approaches (directly) targeting dendritic cell 
(DCs) are illustrated. (A) Adjuvants induce stimulation of DCs, circumventing immaturity and 
potential tolerogenicity. (B) Growth factors trigger DC expansion and often activation. (C) Delivery 
of free or carrier-associated antigen, together with adjuvants, fosters activation of cancer-specific 
T cells by DCs. (D) Direct targeting of (nanoparticle-conjugated) antigen/adjuvant to DCs via DC-
specific antibodies can enhance antigen presentation, cancer-specific T cell activation and reduce 
off-site effects. (E) Schematic workflow of preparation of DC vaccines and effects of their 
administration. Natural DC subsets are isolated from blood and MoDCs differentiated in vitro from 
blood monocytes. After ex vivo activation and antigen-loading, autologous DCs are reinfused into 
the patient to induce antigen-specific T cells with minimal side effects. NAs, neoantigen; TCL, 
tumour cell lysate antigen; TAAs, tumour-associated antigens. 
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Glossary terms: 
 
Pathogen- or danger-associated molecular patterns (PAMPs and DAMPs): 
variety of molecules derived from pathogens or from endogenous danger signals 
that are exposed or released from cells and that alert the immune system and 
activate transduction signals through the interaction with pattern recognition 
receptors.  
 
Tumour microenvironment (TME): usually refers to the non-tumoural cells that 
surround tumour cells, including fibroblasts, blood vessels and immune cells as 
well as the milieu of extracellular factors such as cytokines, soluble molecules 
and extracellular matrix.  
 
Pattern recognition receptors (PRR): germline-encoded host sensors that detect 
PAMPs, although many of them have also been described to sense DAMPs. This 
interaction triggers signalling in the host cell. 
 
Adjuvant: Charles Janeway described adjuvants as the “immunologist’s dirty little 
secret”, as they were substances added to antigens to make vaccines effective, 
but their mode of action was not known at that moment. Adjuvants contain 
chemicals that stimulate the immune system, frequently PAMPs acting on PRRs.   
 
Tumour associated antigens (TAAs): autologous cellular antigen generated in 
tumour cells. They can be the product of mutated genes, antigens produced by 
oncogenic viruses, oncofetal antigens, altered glycolipids and glycoproteins, 
differentiation antigens specific for a cell type and overexpressed or aberrantly 
expressed cellular proteins. 
 
Neoantigen: antigens formed by peptides that are absent from the normal human 
genome. These neo-epitopes can be derived from tumour-specific DNA 
mutations or from viral sequences in the case of virus-associated tumours. 
 
Cross-presentation: presentation in MHC class I of external soluble antigens 
through a process that can be in the endocytic vacuole (vacuolar pathway) 
leading to loading of peptides in MHC-I in the phagosome or can involve the 
transfer of peptides to the cytosol, where exogenous antigens are processed by 
the proteasome and degraded to peptides that are transported to the 
endoplasmic reticulum for loading on MHC-I. The stimulation of naïve cytotoxic 
CD8+ T cells following cross-presentation is known as cross-priming, and is 
needed for anti-tumour immunity. 
 
Immunogenic cell death: form of cell death that induces an effective immune 
response through activation of DCs, in contrast to silent apoptosis, which is not 
immunogenic. 
 
Immune checkpoint blockade (ICB): blockade of specific interactions between 
immune cells (e.g PD1) and cancer cells or other immune cells (e.g. PDL1) that 
dampen immune cell activation. Inhibiting these interactions releases the breaks 
and promotes immune cell activation. 
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Out-of-field or abscopal effects: ability of localized radiation or treatment of a 
tumour to trigger a systemic antitumour effect that can lead to rejection of distant 
tumours or metastases. 
